Skip to content

Study · Randomized controlled trial · n = 156 · 2024

5 results

Trial of Lixisenatide in Early Parkinson's Disease.

Meissner WG, Remy P, Giordana C, Maltête D, Derkinderen P, Houéto JL, Anheim M, Benatru I, Boraud T, Brefel-Courbon C, Carrière N, Catala H and 32 more

Show all authors

Colin O, Corvol JC, Damier P, Dellapina E, Devos D, Drapier S, Fabbri M, Ferrier V, Foubert-Samier A, Frismand-Kryloff S, Georget A, Germain C, Grimaldi S, Hardy C, Hopes L, Krystkowiak P, Laurens B, Lefaucheur R, Mariani LL, Marques A, Marse C, Ory-Magne F, Rigalleau V, Salhi H, Saubion A, Stott SRW, Thalamas C, Thiriez C, Tir M, Wyse RK, Benard A, Rascol O

The New England journal of medicine1 Apr 2024Cited by 298 (Europe PMC)

PMID38598572 (opens in a new tab)DOI10.1056/nejmoa2312323 (opens in a new tab)PepBankPUB-38598572
Publisher pagePubMedAsk about this study
Jump to 5 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study5

5 results from studies that gave the peptide. 5 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In early Parkinson's disease, motor scores changed by -0.04 with lixisenatide versus 3.04 with placebo at 12 months (difference 3.08, 95% CI 0.86 to 5.30, P = 0.007).

    In plain wordsIn early Parkinson's disease, motor disability progressed less with lixisenatide than placebo at 12 months.

    Peptide
    Lixisenatide
    Outcome
    DecreaseMDS-UPDRS part III change at 12 months
    Study

    n = 156

    Comparator
    Placebo
    Analysis
    Primary
    Outcome group
    Exercise and physical function · Nervous system and cognition
    Studied dose
    Dose not stated · subcutaneous · 12 monthsAs given in this study (human).

    Measurements

    MDS-UPDRS part III change at 12 months
    −0.04 points
    lixisenatide
    MDS-UPDRS part III change at 12 months
    3.04 points
    placebo
    Difference in MDS-UPDRS part III change
    3.08 points
    lixisenatide vs placebo; 95% CI 0.86 to 5.30; P = 0.007

    Source sentences

    Summary
    At 12 months, scores on the MDS-UPDRS part III had changed by -0.04 points (indicating improvement) in the lixisenatide group and 3.04 points (indicating worsening disability) in the placebo group (difference, 3.08; 95% confidence interval, 0.86 to 5.30; P = 0.007).
    2 context sentences
    Summary · context
    In this phase 2, double-blind, randomized, placebo-controlled trial, we assessed the effect of lixisenatide on the progression of motor disability in persons with Parkinson's disease.
    Summary · context
    Participants in whom Parkinson's disease was diagnosed less than 3 years earlier, who were receiving a stable dose of medications to treat symptoms, and who did not have motor complications were randomly assigned in a 1:1 ratio to daily subcutaneous lixisenatide or placebo for 12 months, followed by…
  2. 02HumanRandomized controlled trialEfficacy outcome

    In early Parkinson's disease, other secondary endpoint results did not differ substantially between lixisenatide and placebo.

    In plain wordsIn early Parkinson's disease, other secondary results were similar with lixisenatide and placebo.

    Peptide
    Lixisenatide
    Outcome
    No significant changeOther secondary endpoints
    Study

    n = 156

    Comparator
    Placebo
    Analysis
    Secondary
    Outcome group
    Exercise and physical function · Nervous system and cognition
    Studied dose
    Dose not stated · subcutaneous · 12 monthsAs given in this study (human).

    Source sentences

    Summary
    Other results relative to the secondary end points did not differ substantially between the groups.
    3 context sentences
    Summary · context
    Secondary end points included other MDS-UPDRS subscores at 6, 12, and 14 months and doses of levodopa equivalent.
    Summary · context
    In this phase 2, double-blind, randomized, placebo-controlled trial, we assessed the effect of lixisenatide on the progression of motor disability in persons with Parkinson's disease.
    Summary · context
    Participants in whom Parkinson's disease was diagnosed less than 3 years earlier, who were receiving a stable dose of medications to treat symptoms, and who did not have motor complications were randomly assigned in a 1:1 ratio to daily subcutaneous lixisenatide or placebo for 12 months, followed by…
  3. 03HumanRandomized controlled trialEfficacy outcome

    In early Parkinson's disease, off-medication motor scores at 14 months were 17.7 (95% CI 15.7 to 19.7) after lixisenatide versus 20.6 (18.5 to 22.8) after placebo.

    In plain wordsIn early Parkinson's disease, motor scores after washout were lower after lixisenatide than placebo.

    Peptide
    Lixisenatide
    Outcome
    DecreaseOff-medication motor score after washout
    Study

    n = 156

    Comparator
    Placebo
    Outcome group
    Exercise and physical function · Nervous system and cognition
    Studied dose
    Dose not stated · subcutaneous · 12 monthsAs given in this study (human).

    Measurements

    Mean MDS-UPDRS motor score, off-medication, 14 months
    17.7 points
    lixisenatide; 95% CI 15.7 to 19.7
    Mean MDS-UPDRS motor score, off-medication, 14 months
    20.6 points
    placebo; 95% CI 18.5 to 22.8

    Source sentences

    Summary
    At 14 months, after a 2-month washout period, the mean MDS-UPDRS motor scores in the off-medication state were 17.7 (95% CI, 15.7 to 19.7) with lixisenatide and 20.6 (95% CI, 18.5 to 22.8) with placebo.
    2 context sentences
    Summary · context
    In this phase 2, double-blind, randomized, placebo-controlled trial, we assessed the effect of lixisenatide on the progression of motor disability in persons with Parkinson's disease.
    Summary · context
    Participants in whom Parkinson's disease was diagnosed less than 3 years earlier, who were receiving a stable dose of medications to treat symptoms, and who did not have motor complications were randomly assigned in a 1:1 ratio to daily subcutaneous lixisenatide or placebo for 12 months, followed by…
  4. 04HumanNon-randomized trialSafety outcome

    In early Parkinson's disease, nausea occurred in 46% of participants receiving lixisenatide.

    In plain wordsIn early Parkinson's disease, 46% of participants receiving lixisenatide experienced nausea.

    Peptide
    Lixisenatide
    Outcome
    Direction not reportedNausea
    Study

    n = 78

    Outcome group
    Gastrointestinal adverse events · Gastrointestinal
    Studied dose
    Dose not stated · subcutaneous · 12 monthsAs given in this study (human).

    Measurements

    Nausea
    46%
    lixisenatide

    Source sentences

    Summary
    Nausea occurred in 46% of participants receiving lixisenatide, and vomiting occurred in 13%.
    2 context sentences
    Summary · context
    In this phase 2, double-blind, randomized, placebo-controlled trial, we assessed the effect of lixisenatide on the progression of motor disability in persons with Parkinson's disease.
    Summary · context
    Participants in whom Parkinson's disease was diagnosed less than 3 years earlier, who were receiving a stable dose of medications to treat symptoms, and who did not have motor complications were randomly assigned in a 1:1 ratio to daily subcutaneous lixisenatide or placebo for 12 months, followed by…
  5. 05HumanNon-randomized trialSafety outcome

    In early Parkinson's disease, vomiting occurred in 13% of participants receiving lixisenatide.

    In plain wordsIn early Parkinson's disease, 13% of participants receiving lixisenatide experienced vomiting.

    Peptide
    Lixisenatide
    Outcome
    Direction not reportedVomiting
    Study

    n = 78

    Outcome group
    Gastrointestinal adverse events · Gastrointestinal
    Studied dose
    Dose not stated · subcutaneous · 12 monthsAs given in this study (human).

    Measurements

    Vomiting
    13%
    lixisenatide

    Source sentences

    Summary
    Nausea occurred in 46% of participants receiving lixisenatide, and vomiting occurred in 13%.
    2 context sentences
    Summary · context
    In this phase 2, double-blind, randomized, placebo-controlled trial, we assessed the effect of lixisenatide on the progression of motor disability in persons with Parkinson's disease.
    Summary · context
    Participants in whom Parkinson's disease was diagnosed less than 3 years earlier, who were receiving a stable dose of medications to treat symptoms, and who did not have motor complications were randomly assigned in a 1:1 ratio to daily subcutaneous lixisenatide or placebo for 12 months, followed by…

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials2

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

2 trials · 1 ongoing · 1 completed · source ClinicalTrials.gov (opens in a new tab)

RecruitingPhase not statedNCT07207148

People With Multiple Sclerosis Treated With Ocrelizumab and GLP-1 Agonists

Northwestern Universityn = 10015 Nov 2025 to est. 31 Aug 2028

Multiple Sclerosis

Trial pageClinicalTrials.govUpdated 17 Mar 2026
CompletedPhase 2NCT03439943

Study to Evaluate the Effect of Lixisenatide in Patient With Parkinson's Disease

University Hospital, Toulousen = 15613 Jun 2018 to 15 Apr 2021

Parkinson Disease

Trial pageClinicalTrials.govUpdated 28 Nov 2025

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:36 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.